Asset profile

Melatonin prolonged-release · Circadin

Unknown / undisclosed

Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page
Phase 3underway

Evidence outlook · registrational

Registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. No upcoming registrational readout date is posted to the registry. Check News for topline announcements.

How the evidence outlook works ↗

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
December 2026 (1)
Early phase / not applicablePreoperative AnxietyRecruiting
Est. primary completion 2026-12-15 · NCT06489327 · CT.gov ↗
What to watch
Unlock with Research ↗
2027 (2)
April 2027 (1)
Phase 4IBD (Inflammatory Bowel Disease)Recruiting
Est. primary completion 2027-04-01 · NCT07737665 · CT.gov ↗
What to watch
Unlock with Research ↗
December 2027 (1)
Phase 4Hypoactive DeliriumRecruiting
Est. primary completion 2027-12 · NCT03438526 · CT.gov ↗
What to watch
Unlock with Research ↗

See the full readout calendar ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.

Phase 3 (2)
Phase 2 (5)
Phase 1 (2)
Phase 4 (7)
Early phase / not applicable (1)
Appears in other studies (1)